Compare Biodesix, Inc. with Similar Stocks
Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -8.74% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -5.37
2
Flat results in Jun 25
3
Risky - Negative EBITDA
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
USD 87 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-18.47
2,267.54%
-50.73
Revenue and Profits:
Net Sales:
22 Million
(Quarterly Results - Sep 2025)
Net Profit:
-9 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
33.25%
0%
33.25%
6 Months
33.08%
0%
33.08%
1 Year
-50.1%
0%
-50.1%
2 Years
-74.31%
0%
-74.31%
3 Years
413.86%
0%
413.86%
4 Years
-85.93%
0%
-85.93%
5 Years
-97.63%
0%
-97.63%
Biodesix, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
28.86%
EBIT Growth (5y)
-8.74%
EBIT to Interest (avg)
-5.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.82
Sales to Capital Employed (avg)
1.49
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
37.48%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.01
EV to EBIT
-1.99
EV to EBITDA
-2.40
EV to Capital Employed
2.07
EV to Sales
0.87
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-103.88%
ROE (Latest)
-350.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Bullish
Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 6 Schemes (2.75%)
Foreign Institutions
Held by 13 Foreign Institutions (1.9%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
21.80
20.00
9.00%
Operating Profit (PBDIT) excl Other Income
-5.70
-8.30
31.33%
Interest
2.10
1.90
10.53%
Exceptional Items
-0.00
0.10
-100.00%
Consolidate Net Profit
-8.70
-11.50
24.35%
Operating Profit Margin (Excl OI)
-323.60%
-484.20%
16.06%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 9.00% vs 11.11% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 24.35% vs -3.60% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
71.30
49.10
45.21%
Operating Profit (PBDIT) excl Other Income
-28.80
-35.80
19.55%
Interest
7.10
9.50
-25.26%
Exceptional Items
-1.60
-1.30
-23.08%
Consolidate Net Profit
-42.90
-52.10
17.66%
Operating Profit Margin (Excl OI)
-480.30%
-841.30%
36.10%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 45.21% vs 28.53% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 17.66% vs 20.34% in Dec 2023
About Biodesix, Inc. 
Biodesix, Inc.
Pharmaceuticals & Biotechnology
Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.
Company Coordinates 
Company Details
2970 Wilderness Place, Suite 100 , BOULDER CO : 80301
Registrar Details






